A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
NCT05744466 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500
Last updated 2024-07-23
Summary
The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.
Conditions
Interventions
- DRUG
-
As prescribed by treating clinician
- DRUG
-
Apremilast
As prescribed by treating clinician
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-09-30
- Primary Completion
- 2027-12-10
- Completion
- 2027-12-10
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
NCT04908189 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.
NCT02425826 ·Status: COMPLETED ·Phase: PHASE4
-
A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT03410992 ·Status: COMPLETED ·Phase: PHASE3
-
Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy
NCT03721172 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis
NCT03624127 ·Status: COMPLETED ·Phase: PHASE3
-
Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis
NCT00521339 ·Status: COMPLETED ·Phase: PHASE2
-
A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
NCT06701513 ·Status: RECRUITING
-
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
NCT06042920 ·Status: TERMINATED ·Phase: PHASE4
-
Long-Term Follow-Up Study of Psoriasis Patients
NCT00131066 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453 ·Status: RECRUITING ·Phase: PHASE3
-
A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
NCT06952465 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan
NCT05633264 ·Status: COMPLETED
-
A Study to Assess Treatment Patterns, Clinical Outcomes and Healthcare Resource Utilization Among Adult Participants With Moderate-To-Severe Plaque Psoriasis
NCT05547490 ·Status: COMPLETED
-
Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain
NCT03539419 ·Status: COMPLETED
-
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).
NCT04428411 ·Status: COMPLETED
-
A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)
NCT06122649 ·Status: COMPLETED ·Phase: PHASE3
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)
NCT02346240 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
NCT01690299 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
NCT01154101 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis
NCT04772079 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)
NCT00773734 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT03982394 ·Status: COMPLETED